BRIEF-U.S. FDA wants more information on Astra lung drug

LONDON, Aug 30 (BestGrowthStock) – AstraZeneca says its MedImmune
biologics unit has received a request from the U.S Food and Drug
Administration for more information on its infant lung drug
motavizumab.

The letter from the U.S. medicines regulator asked for
evidence from an additional clinical trial that supports a
satisfactory risk/benefit profile in the population for which
the prophylaxis indication is being requested, Astra said on
Monday.
(Reporting by Kate Kelland; Editing by Dan Lalor)

BRIEF-U.S. FDA wants more information on Astra lung drug